Expand DBVT Menu
DBVT MENU

DBVT Latest Press Releases

-- February 28, 2026 --

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Globe Newswire 2:25 PM

-- February 10, 2026 --

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting Globe Newswire 4:30 PM

-- February 9, 2026 --

DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit Globe Newswire 4:30 PM

-- February 5, 2026 --

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 Globe Newswire 4:30 PM

-- January 16, 2026 --

DBV Technologies Announces EUR 166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing Globe Newswire 6:11 PM

-- January 12, 2026 --

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 Globe Newswire 4:00 PM

-- January 7, 2026 --

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF Globe Newswire 4:00 PM

-- January 5, 2026 --

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 Globe Newswire 4:00 PM

-- December 16, 2025 --

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years Globe Newswire 4:05 PM

-- December 2, 2025 --

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 Globe Newswire 4:00 PM

-- November 11, 2025 --

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years Globe Newswire 11:50 PM

-- November 4, 2025 --

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference Globe Newswire 4:30 PM

-- November 3, 2025 --

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer Globe Newswire 4:30 PM
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 Globe Newswire 4:25 PM

-- October 30, 2025 --

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors Globe Newswire 4:30 PM
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting Globe Newswire 3:00 AM

-- October 29, 2025 --

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Globe Newswire 6:47 PM

-- October 28, 2025 --

DBV Technologies Reports Third Quarter 2025 Financial Results Globe Newswire 4:25 PM

-- October 6, 2025 --

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Globe Newswire 5:02 PM
Market Data Delayed 15 Minutes